CONTERA PHARMA A/S
Core data
Name | CONTERA PHARMA A/S |
Address | Venlighedsvej 4, 2970, Hørsholm |
Founded | Jul 9, 2010 |
| 21 / 19 | |
Locations (P-units) | 1View locations |
Website | https://conterapharma.com/ |
| contera-pharma | |
VAT registered | |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Name | CONTERA PHARMA A/S |
Address | Venlighedsvej 4, 2970, Hørsholm |
Founded | Jul 9, 2010 |
| 21 / 19 | |
Locations (P-units) | 1View locations |
Website | https://conterapharma.com/ |
| contera-pharma | |
VAT registered | |
Branch | Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000) |
Keep track of CONTERA PHARMA A/S
Description
Contera Pharma is a Danish biotech company transforming RNA therapeutics with a proprietary discovery platform that uncovers new opportunities in diseases with significant unmet needs. It develops innovative treatments for neurological disorders.
Contera Pharma uses a precision medicine approach and a proprietary discovery platform to identify human disease-validated drug discovery targets and develop novel therapeutic and pipeline opportunities for neurological disorders. It also pursues partnerships and licensing opportunities.
Company's own description on virk.dk
Description of key activities of the companyLike previous years, the activities are development of new pharmaceuticals and other related activities.
Products & services
Proprietary RNA therapeutics discovery platform · Drug discovery target identification · CP-012 for Parkinson’s disease · CP-102 antisense oligonucleotide therapy for Canavan disease · Research collaborations · Partnering and licensing opportunities
Industries
Biotechnology · Pharmaceutical drug discovery · RNA therapeutics · Neurological disorders
Customer types
Patients with neurological disorders · Academic institutions and companies
Analysis by AI ✨
Contera Pharma reported a markedly improved result in 2025 compared with the previous year: gross profit was DKK 20.6 million, against DKK -54.1 million in 2024, and profit after tax was DKK -4.8 million, against DKK -69.2 million. The annual report describes the company's activities as developing new pharmaceuticals and related activities.
The workforce grew from 20 employees in July 2026 to 21 in August 2026. The company is based in Hørsholm; its current address, Venlighedsvej 4, has been in effect since 10 October 2022.
Bukwang Pharmaceutical Co., Ltd currently owns 90–99.99% of Contera Pharma. The South Korean company has been an owner since 24 November 2014, with historical changes in its ownership stake; its currently registered stake is 90–99.99%. Medici 2020-1 Private Equity Fund, a South Korean fund, held a historical stake of 25–33.32% from 22 July 2020 to 1 April 2024.
The share capital was increased by a nominal DKK 1,490,566 on 14 July 2026. The latest annual report also states that, after the financial year ended, the board decided to initiate a process aimed at a demerger; it was expected to be completed in 2026 and was subject to approval by the general meeting and relevant authorities.
AI-generated texts are based on registered information, which may be delayed or incomplete. Errors may occur.
Financials
| Reporting period | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross profit | 20,632,306 | ||||||||
| Operating profit | -5,983,680 | ||||||||
| Profit before tax | -6,062,659 | ||||||||
| Net income | -4,783,781 | ||||||||
| Total assets | 97,550,947 | ||||||||
| Equity | 79,471,802 | ||||||||
| Avg. employees | 14 | ||||||||
2017–2025 Unlock financial history | |||||||||
Datapublica Risk Score
What goes into the assessment
Financials
Equity ratio, profitability, and liquidity
Accounts and history
Late filings and previous financial distress
Owners and management
Past bankruptcies and owners’ other companies
Company and connections
Age, industry, and shared addresses or contact details
Standard: Score and risk bandPro: Also a detailed explanation of the factors
Contact
From conterapharma.com
| Contact | Phone | |
|---|---|---|
| Main | — | in**@conterapharma.comShow full |
Gazelle
2 consecutive growth years
Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.
People
| Person | Roles | Titles |
|---|---|---|
| Paul Ejnar Gremaud Kristjansen | Roles Board | TitlesBESTYRELSESMEDLEM |
| Thomas Nikolaj Sager | Roles BoardManagement | TitlesBESTYRELSESMEDLEM • ADM. DIR. |
Auditor
| Audit firm | Auditor | Role | From |
|---|---|---|---|
| PKF Munkebo Eriksen Funch, Statsautoriseret Revisions aktie selskab | AuditorThomas Funch | RoleStatsautoriseret revisor | FromApr 15, 2026 |
Legal owners
| Owner | Ownership | Voting rights | From |
|---|---|---|---|
Foreign legal entity | Ownership90–99.99 % | Voting rights90 % | FromApr 1, 2024 |
Ultimate owners
| Name | Ownership through | Calculated ownership |
|---|---|---|
| 🇰🇷Bukwang Pharmaceutical Co., Ltd | Ownership through Direct | 90–99.99 % |